Dow Jones Top Company Headlines at 5 AM ET: Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study | ...
1h
How JPMorgan became the latest Wall Street firm to have its research in Scott Bessent's crosshairs
JPMorgan's head of global commodities research, Natasha Kaneva, is the latest Wall Street researcher to draw the ire of ...
"I've searched. I've networked. I've tried seemingly everything." (Photo subject is a model.) ...
Morgan Stanley's Mike Wilson told clients that he expects that U.S. outperformance could continue. He said the U.S. market ...
U.S. futures for the S&P 500 were down 1.5% and futures for the Dow Jones Industrial Average fell 1.6%. Changes in futures do ...
GSK said it would sell rights to linerixibat, an experimental treatment for itching caused by a liver disease, to Italian ...
Dow Jones Industrial Average futures (YM00) fell more than 1,000 points, or 2.3% on Sunday. S&P 500 futures (ES00) were down ...
Dow Jones Top Company Headlines at 3 AM ET: Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study | Activist ... Roche Breast-Cancer Treatment Falls Short of Primary Goal in ...
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
Roche Holding said a drug combination including a new experimental breast-cancer treatment fell short of its primary ...
The U.S. is ending the winter heating season with plenty of gas in storage, unlike in Europe, where inventories are unusually ...
Novo Nordisk reportedly will strike a deal with Hims & Hers. Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results